vs
Side-by-side financial comparison of NIP Group Inc. (NIPG) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $39.3M, roughly 1.7× NIP Group Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -11.9%, a 51.3% gap on every dollar of revenue.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
NIPG vs SLNO — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.3M | $66.0M |
| Net Profit | $-4.7M | $26.0M |
| Gross Margin | 6.0% | 98.3% |
| Operating Margin | -13.0% | 33.5% |
| Net Margin | -11.9% | 39.4% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 134.0% |
| EPS (diluted) | — | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $66.0M | ||
| Q2 25 | — | $32.7M | ||
| Q2 24 | $39.3M | — |
| Q3 25 | — | $26.0M | ||
| Q2 25 | — | $-4.7M | ||
| Q2 24 | $-4.7M | — |
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q2 24 | 6.0% | — |
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | -20.0% | ||
| Q2 24 | -13.0% | — |
| Q3 25 | — | 39.4% | ||
| Q2 25 | — | -14.4% | ||
| Q2 24 | -11.9% | — |
| Q3 25 | — | $0.47 | ||
| Q2 25 | — | $-0.09 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.8M | $498.9M |
| Total DebtLower is stronger | $3.8M | — |
| Stockholders' EquityBook value | — | $494.8M |
| Total Assets | $305.3M | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $498.9M | ||
| Q2 25 | — | $286.8M | ||
| Q2 24 | $6.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | $3.8M | — |
| Q3 25 | — | $494.8M | ||
| Q2 25 | — | $240.1M | ||
| Q2 24 | — | — |
| Q3 25 | — | $599.9M | ||
| Q2 25 | — | $332.3M | ||
| Q2 24 | $305.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q2 24 | — | — |
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q2 24 | — | — |
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | -38.6% | ||
| Q2 24 | — | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q2 24 | — | — |
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
